<DOC>
	<DOC>NCT00655486</DOC>
	<brief_summary>The purpose of this study is to allow eligible subjects from the parent study, SP925 [NCT00655551] to continue lacosamide and to obtain additional long-term safety data</brief_summary>
	<brief_title>Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures</brief_title>
	<detailed_description>A multicenter, open-label extension study to assess the long-term safety and tolerability of lacosamide as adjunctive therapy in subjects with partial-onset seizures who were previously enrolled in the SP925 study [NCT00655551] (intravenous lacosamide loading dose followed by approximately 1 week of oral lacosamide maintenance).</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies, Partial</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Eligible subjects who participated in SP925 [NCT00655551] for treatment of partialonset seizures Receiving any study drug or experimental device other than lacosamide Meets withdrawal criteria for parent study SP925 [NCT00655551] Experiencing ongoing serious adverse event</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>seizures</keyword>
	<keyword>antiepileptic</keyword>
	<keyword>Lacosamide</keyword>
	<keyword>Vimpat</keyword>
	<keyword>safety</keyword>
	<keyword>adjunctive</keyword>
</DOC>